Posttreatment with sodium arsenite is coclastogenic in log phase but not in stationary phase.
Posttreatment with sodium arsenite in log phase synergistically increases the chromosomal aberrations induced by ethyl methanesulfonate in Chinese hamster ovary cells, human fibroblasts, and human lymphocytes. However, posttreatment with sodium arsenite in stationary phase has no apparent effect on the clastogenicity of ethyl methanesulfonate. These results indicate that the cycling state of the cell plays a crucial role in the action of arsenite coclastogenicity. One prediction from this finding is that in combined treatment, posttreatment with sodium arsenite should preferentially kill cancer cells.
D000818:Animals; D001151:Arsenic / Q000633:toxicity*; D018053:Arsenites; D002453:Cell Cycle; D002478:Cells, Cultured; D002869:Chromosome Aberrations / Q000187:drug effects*; D006224:Cricetinae; D003412:Cricetulus; D004357:Drug Synergism; D005020:Ethyl Methanesulfonate / Q000633:toxicity; D005347:Fibroblasts / Q000648:ultrastructure; D006801:Humans; D008214:Lymphocytes / Q000648:ultrastructure; D009153:Mutagens; D017670:Sodium Compounds
D018053:Arsenites; D009153:Mutagens; D017670:Sodium Compounds; C017947:sodium arsenite; D005020:Ethyl Methanesulfonate; D001151:Arsenic